| Name | Title | Contact Details |
|---|
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.
Adare Pharma Solutions is a global contract development and manufacturing organization (CDMO) focused on oral dosage forms for the pharmaceutical industry. The company offers integrated services that span from product development to commercial manufacturing and packaging, with a strong emphasis on small molecule pharmaceuticals. With around 800 employees and seven facilities in the United States and Europe, Adare is well-equipped to serve markets worldwide. The company specializes in technologies such as taste masking, customized release, and solubility enhancement, addressing unique formulation challenges. Adares product development services include formulation development, analytical method validation, and support for various regulatory submissions. Their manufacturing capabilities encompass a range of processes, including granulation, coating, and high potency manufacturing. Additionally, Adare operates a dedicated packaging facility that provides high-speed packaging solutions. The company serves a diverse customer base, including branded, specialty, generic, and veterinary pharmaceutical segments, and is committed to maintaining high regulatory standards across all operations.
Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.
INVO Bioscience is a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our INVOcell® Culture Device is a patented medical device used in the treatment of infertility that enables egg fertilization and early embryo development to take place in the woman`s body, in vivo. This revolutionary device promotes in vivo conception. It is an FDA cleared Intravaginal Culture (IVC) device that is a safe, effective and economical fertility treatment.
Allcells LLC is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.